4.43
-0.45%
Close of 9 Nov 2026, in HKD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Grand Pharmaceutical Group
Its shares trade on HKEX under the ticker 0512.HK. It has been listed since 19 December 1995. In the fiscal year to 31 December 2025, it reported revenue of HK$12.28bn and net income of HK$1.24bn. At that date it held total assets of HK$27.17bn and shareholders' equity of HK$17.02bn.
China Grand Pharmaceutical & Healthcare Holdings Ltd. engages in the development, manufacture and distribution of pharmaceutical products. The company employs 8,213 full-time employees The main businesses of the Company include the research and development, manufacture and sales of pharmaceutical products, medical products, chemical products and healthcare products. The products of the Company include preparations, raw materials, medical devices, healthcare products, as well as agricultural and fine chemicals. Its products mainly focus on ophthalmic, cardiovascular and antibacterial, among others.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 19 Dec 1995
- Employees
- 8,213
- Website
- chinagrandpharm.com ↗
Leadership
Pay as last reported
- Mr. Xiaofeng ShiChairman of the Board of Grand Pharma, China
- Ms. Chit Yee LamExecutive Director, since 2024
- Mr. Guang YangExecutive Director, since 2023
- Mr. Chao ZhouExecutive Director, since 2021
- Mr. Tin Chung FooCompany Secretary
- Mr. Yebi HuIndependent Non-Executive DirectorHK$100,000
- Dr. Geng PeiIndependent Non-Executive DirectorHK$60,000
- Ms. Tosi Wan SoIndependent Non-Executive DirectorHK$180,000
- Dr. Li Na XingNon-Executive Independent Director
- Dr. Weikun TangExecutive Chairman of the Board; President of Grand Pharma, China, since 2021HK$1.1m
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- China Grand Pharmaceutical and Healthcare Holdings Ltd holds a strong position in the pharmaceutical and healthcare industry in China. With its extensive product portfolio and well-established distribution network, the company has gained a significant market share.
- The company heavily invests in research and development, which allows it to continuously innovate and develop new drugs and healthcare solutions. This helps China Grand Pharmaceutical and Healthcare Holdings Ltd stay ahead of its competitors and offer cutting-edge products.
- The company offers a wide range of pharmaceutical products, including prescription drugs, over-the-counter medications, and healthcare devices. This diversification in product offerings enables China Grand Pharmaceutical and Healthcare Holdings Ltd to cater to various customer needs and capture a larger market share.
Weaknesses
- China Grand Pharmaceutical and Healthcare Holdings Ltd heavily relies on the domestic Chinese market for its revenue. This concentration exposes the company to risks associated with changes in government regulations, market fluctuations, and economic conditions within China.
- The company has a relatively limited international presence compared to some of its global competitors. This restricts its access to overseas markets and potential growth opportunities beyond China.
- While China Grand Pharmaceutical and Healthcare Holdings Ltd is well-known within the Chinese market, it still faces challenges in achieving strong brand recognition on a global scale. Building a reputable brand presence internationally may require additional investments and marketing efforts.
Opportunities
- China's healthcare market is experiencing rapid growth due to an aging population, increasing disposable income, and government initiatives to enhance healthcare infrastructure. China Grand Pharmaceutical and Healthcare Holdings Ltd can capitalize on this favorable market environment to expand its business and increase sales.
- The company has the potential to expand its operations beyond China and tap into the global pharmaceutical and healthcare markets. Strategic partnerships, acquisitions, and investments in research collaborations could help China Grand Pharmaceutical and Healthcare Holdings Ltd establish a stronger international presence.
- Advancements in technology, such as digital health solutions, can provide opportunities for China Grand Pharmaceutical and Healthcare Holdings Ltd to develop innovative products and services that cater to the evolving needs of healthcare consumers.
Threats
- The pharmaceutical and healthcare industry is highly competitive, both domestically and internationally. China Grand Pharmaceutical and Healthcare Holdings Ltd faces competition from both established players and emerging companies, which can impact its market share and profitability.
- Government regulations and policies relating to pharmaceuticals and healthcare can change frequently, posing risks and uncertainties for China Grand Pharmaceutical and Healthcare Holdings Ltd. Compliance with evolving regulations and potential policy shifts can impact the company's operations and financial performance.
- The healthcare industry is subject to pricing pressure, driven by factors such as government cost containment efforts, increasing generic competition, and negotiations with healthcare payers. China Grand Pharmaceutical and Healthcare Holdings Ltd must carefully manage pricing strategies to maintain profitability in this challenging market environment.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.